Exchange: NYSE·Updated 07:57 PM EDT

ABBV News

News
all
press releases
Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle
Key PointsAbbVie is the exact opposite of a high-yield trap...
Nasdaq News: Markets
Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle
Key PointsAbbVie is the exact opposite of a high-yield trap...
Nasdaq News: Markets
More News
SKYRIZI (risankizumab) and RINVOQ (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
SKYRIZI (risankizumab) and RINVOQ (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026 SKYRIZI (risankizumab) and RINVOQ (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel...
PR Newswire
Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends
Key PointsAbbVie is a resilient Dividend King with a wide moat...
Nasdaq News: Markets
5 Stock Ideas for Your Short List
Forget the AI stocks. These five stocks have momentum right now.
Zacks
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?
Sanofi's upgraded 2026 outlook, Dupixent growth and attractive valuation give it an edge over AbbVie, despite pipeline setbacks and vaccine sales challenges.
Zacks
Bet on These Healthcare ETFs to Benefit From the Aging US Population
With the US population aging rapidly, three healthcare ETFs offer exposure to companies developing treatments, drugs and medical devices for age-related conditions.
Zacks
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Zacks
AbbVie's Subcutaneous Skyrizi Shows Endoscopic Benefits In Crohn's Diseases
(RTTNews) - Tuesday, AbbVie reported new Phase 3 AFFIRM data showcasing endoscopic outcomes with subcutaneous Skyrizi in adults with moderately to severely active Crohn's disease...
Nasdaq News: Markets
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsAbbVie is aggressively diversifying its pipeline to mitigate the revenue impact from its loss of patent exclusivity on Humira...
Nasdaq News: Markets
AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsAbbVie continues to diversify its portfolio through the successful expansion of newer therapies like Skyrizi and Rinvoq...
Nasdaq News: Markets

Advertisement|Remove ads.